Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer
As a member of helix–loop–helix protein family, transcription factor 12 functions as either an oncogene or a tumor suppressor in various human cancers. However, there are no reports on its involvement in prostate cancer. To investigate clinical relevance of transcription factor 12 in prostate cancer...
Saved in:
| Main Authors: | Qing-biao Chen, Ying-ke Liang, Yan-qiong Zhang, Min-yao Jiang, Zhao-dong Han, Yu-xiang Liang, Yue-ping Wan, Jie Yin, Hui-Chan He, Wei-de Zhong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-06-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317703924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Functional analyses of splice site variants in TCF12
by: Angela Borst, et al.
Published: (2025-04-01) -
Racial Disparities in Prostate Cancer Incidence, Biochemical Recurrence, and Mortality
by: Cathryn H. Bock, et al.
Published: (2011-01-01) -
Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
by: John M. Lacy, et al.
Published: (2016-01-01) -
De Novo Splice Site Variant of TCF12 in a Boy With Isolated Kallmann Syndrome
by: Erina Suzuki, et al.
Published: (2025-01-01) -
Development of a deep learning system for predicting biochemical recurrence in prostate cancer
by: Lu Cao, et al.
Published: (2025-02-01)